Most Viewed Articles About Biosimilar Articles

Biosimilars started to gain a firm foothold in the market this year and could take off in 2023 with the advent of Humira biosimilars. Our articles about biosimilars were some of the most viewed of the year.

Humira Biosimilars Are Hitting the Market in 2023. Finally. But Will Prescriptions Follow?

Marcus Snow, M.D., chair of the American College of Rheumatology’s Committee on Rheumatologic Care, discusses how additional clinical data and interchangeability designations could help build momentum for use of Humira (adalimumab) biosimilars when they start to arrive in 2023.

Read more

Biosimilars Can Help Lower Patient Drug Costs When the Right Teams Come Together: Prime Therapeutics Executive

Pharmacy benefit managers can help health plans understand when to best leverage and align to biosimilars and other cost-effective treatments, argues Prime Therapeutics' Kelly McGrail-Pokuta.

Read more

Efforts Are Needed from Payers for Improvements in Biosimilars

Efforts to improve education on biosimilars are a start, but payer policies must catch up to ensure real change.

Read more

Researchers Identify a Communications Breakdown Over Herceptin Biosimilars

If biosimilar acceptance is to grow, it’s going to take a great deal of work to improve the levels of trust between payers, patients, and oncologists.

Read more

Humira, the biosimilars are coming, the biosimilars are coming!

Circle 2023 on your calendar. That's when as many as 11 biosimilars to Humira are headed for the U.S. market.

Read more